The largest database of trusted experimental protocols

4 protocols using cd64 bv421

1

Monoclonal Antibody Optimization for THP-1 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Optimal concentrations of monoclonal antibody combinations directed against the following human surface antigens: HLA-DR-FITC, CD181-FITC (CXCR1), CD86-PE, CD282-PE (TLR2), CD80-PerCP/Cy5.5, CD11b-PerCP/Cy5.5, CD16-PE/Cy7, CD163-PE/Cy7, CD197-APC (CCR7), CD284-APC (TLR4), CD206-APC/Cy7, CD64-BV421, CD14-BV510 (BioLegend) were incubated with THP-1 cells stimulated with IL-1β/IL-1Ra. Isotype matched FITC, PE, PerCP/Cy5.5, PE/Cy7, APC and APC/Cy-7-conjugated irrelevant antibodies (BioLegend) were used as negative controls. Antigen expression was analyzed on a BD FACSCanto II cytometer (BD Biosciences, San Jose, CA). Obtained data were analyzed using FlowJo V10 software (FlowJo, Ashland, OR, USA). In all experiments, a minimum of 10,000 events were counted. Results were expressed as a percentage and median fluorescence intensity (MFI) of the cells for each examined marker.
+ Open protocol
+ Expand
2

Monocyte and DC Recruitment in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
To analyze monocyte and DC recruitment in response to CpG, 20 µl of a 100 µg/ml ODN1864 solution was injected into the footpad of C57BL/6 J mice. At the indicated time intervals post injection, blood samples were collected through the tail vein followed by ACK (Thermo Fisher Scientific) mediated red blood cell lysis. Alternatively, mice were euthanized and the DLNs were dissected. Single cell suspensions of DLN were prepared through incubation with collagenase type IV (Sigma-Aldrich) and passed through a 70 µm cell strainer (BD Falcon).
After treatment with 2.4G2 Ab for 5 min to block the FcR, PBMCs or lymph node cell suspensions were stained with the following anti-mouse Abs: anti-CD45-V450, anti- MHCII-FITC, anti-CD86-PE, anti-CD40- PE, anti-CD64-APC, anti-F4/80-APC, anti-Ly6C-PE-Cy7, anti-CD11b-APC-Cy7 (all BD Biosciences), Ly6G-PerCP-Cy5.5, CCR2-APC (eBioscience), CD64-BV421 (BioLegend) and CD11c-PE-TxR (R & D systems). Death cells were identified by staining with aqua life/dead stain (Invitrogen). Fluorescent events were acquired using an LSRII flow cytometer (BD Biosciences) and analyzed using FlowJo software. After exclusion of dead cells, granulocytes were identified as CD45+ CD11b+ Ly6C+ Ly6G+ cells and Monocytes as CD45+ Ly6Chi CD11bhi Ly6G- cells. Following exclusion of granulocytes and Monocytes in the LN, DCs were subdivided into MHCIIhi DCs and MHCIIint DCs.
+ Open protocol
+ Expand
3

Comprehensive Flow Cytometric Phenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols
Lysed EDTA‐anticoagulated peripheral blood and 106 splenocytes were incubated with Fc block anti‐CD16/32 (Biolegend, San Diego, CA, USA) before the addition of the antibody mix. Fluorophore‐labelled anti‐mouse antibodies against CD19‐PE (Becton Dickinson, Franklin Lakes, NJ, USA), Ly6G‐PE (Becton Dickinson, Franklin Lakes, NJ, USA), CD49b‐PE (Biolegend, San Diego, CA, USA), CD90.2‐PE (Becton Dickinson, Franklin Lakes, NJ, USA), CD11b‐PE‐Cy7 (Becton Dickinson), CD11c‐APC, Cy7 (Becton Dickinson, Franklin Lakes, NJ, USA), Ly6C‐APC (Becton Dickinson, Franklin Lakes, NJ, USA), MHCII‐BB515 (Becton Dickinson, Franklin Lakes, NJ, USA), and CD64‐BV421 (Biolegend, San Diego, CA, USA) were diluted to appropriate working concentrations as provided by the manufacturer. Live/dead fixable aqua stain (Invitrogen, Waltham, MA, USA) was added. Samples were measured in a BD LSR II Flow cytometer. Analysis was performed in FlowJo V10. The gating strategy9 can be found in Supporting Information Figure S1.
+ Open protocol
+ Expand
4

Multiparameter Flow Cytometry Panel

Check if the same lab product or an alternative is used in the 5 most similar protocols
PD-1 FITC (1:300; J43; eBioscience), NK1.1 PE (1:300; PK136; eBioscience), CD3e PE-Dazzle594 (1:300; 145-2C11; BioLegend), CD3e PE (1:200; 145-2C11; eBioscience), FoxP3 PerCP-Cy5.5 (1:200; FJK-16s; eBioscience), CD8a PE-Cy7 (1:2000; 53-6.7; eBioscience), CD8a APC (1:600; 53-6.7; eBioscience), CD8a PerCP-Cy5.5 (1:400; 53-6.7; eBioscience), TCRb AF700 (1:100; H57-597; BioLegend), CD45 BV785 (1:1000; 30-F11; BioLegend), CD4 BV711 (1:400; GK1.5; BioLegend), CD19 BV650 (1:400; 6D5; BioLegend), CD19 PE (1:500; 1D3; eBioscience), CD11b BV605 (1:1000; M1/70; BioLegend), CD11b BV510 (1:400; M1/70; BioLegend), CD11c BV605 (1:400; N418; BioLegend), Siglec-F PE (1:300; E50-2440; BD Biosciences), F4/80 APC (1:200; BM8; BioLegend), Ly-6G AF 700 (1:300; 1A8; BioLegend), MHC II BV650 (1:4000; M5/114.15.2; BioLegend), CD64 BV421 (1:200; X54-5/7.1; BioLegend), TNF FITC (1:300; MP6-XT22; BioLegend), IFNg PE-Cy7 (1: 1000; XMG1.2; BD Biosciences), Eomes PE (1:200; W17001A; BioLegend), Ki-67 BV 650 (1:200, 11F6; Biolegend), GzmB FITC (1:100; GB11; BioLegend). Gating strategy is depicted in Supplementary Fig. 6d.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!